Story perspectives

FDA's Fast-Track Drug Program Sparks Safety Concerns

1/17/2026

45 10

Summary

Story summary

The U.S. Food and Drug Administration's National Priority Voucher program aims to expedite approvals.
The program raises concerns about political interference and potential compromises to safety standards.
Staff report confusion and anxiety as senior officials assume decisions once reserved for scientific reviewers.
Drugmakers like Eli Lilly press for faster approvals, driving departures from established timelines.
Experts warn the changes may not endure beyond the current administration.

1 of 1

Story summary

The U.S. Food and Drug Administration's National Priority Voucher program aims to expedite approvals.
The program raises concerns about political interference and potential compromises to safety standards.
Staff report confusion and anxiety as senior officials assume decisions once reserved for scientific reviewers.
Drugmakers like Eli Lilly press for faster approvals, driving departures from established timelines.
Experts warn the changes may not endure beyond the current administration.